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segment late loss as the primary study end-point did not significantly differ among the
ZES group and the SES group (0.14±0.38 mm vs. 0.12±0.43 mm, P for
noninferiority=0.03, P for superiority=0.68). The rates of in-segment binary restenosis
was 5.2% in the ZES group and 7.2% in the SES group (P=0.44). The in-stent late loss
(0.26±0.36 mm vs. 0.24±0.42 mm, P=0.78) and in-stent binary restenosis rate (4.0%
vs. 6.0%, P=0.41) were also similar among 2 groups. There were no significant
between-group differences in the rate of adverse events (death, myocardial infarction,
stent thrombosis, target-lesion revascularization, and composite outcomes).
Conclusion: For patients with long native coronary artery disease, as compared with
SES implantation, the Resolute ZES showed similar angiographic late loss and
restenosis rates. Clinical safety and efficacy outcomes were also similar between two
stent groups.
Unprotected Left Main Stenting with Everolimus-Eluting Stent:
PRECOMBAT-2 Study
Seung-jung Park, Young-Hak Kim, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee,
Cheol Whan Lee, Seong-Wook Park, Yangsoo Jang, Myung-Ho Jeong, Hyo-Soo Kim,
Seung Ho Hur, Seung Un Na, Sung-Ho Her, Do-Sun Lim, Ki Bae Seung, In-Whan
Seong, Jun-Hong Kim, Sang Gon Lee
Background: The PRECOMBAT randomized study showed a non-inferiority of
percutaneous coronary intervention (PCI) with the first-generation sirolimus-eluting
stent (SES) for unprotected left main coronary artery (ULMCA) stenosis compared
with coronary artery bypass graft (CABG) surgery with regard to the incidence of 1-
year major adverse cardiac or cerebrovascular events (MACCE) including death,
myocardial infarction (MI), stroke or ischemia- driven target vessel revascularization
(TVR). However, the safety and efficacy of the second-generation drug-eluting stent
for such lesions are not known well.
Methods: The PRECOMBAT-2 study prospectively enrolled 397 consecutive patients
who received PCI with everolimus-eluting stent (EES) for ULMCA stenosis. From
this registry, the outcomes of 334 (84.1%) patients meeting the randomization criteria
of the PRECOMBAT study were compared with those of patients randomized to SES
(N=327) and CABG (N=272) in the PRECOMBAT study (Figure 1). The primary end
point was the rate of MACCE over 2 years.
Results: Baseline clinical characteristics were well matched among the 3 groups.
Angiographic follow-up was less frequently performed in the EES than in the SES
group due to the less obligatory recommendation (60.8% vs. 76.1%, p<0.001). The
MACCE rate over 2 years did not differ significantly among the 3 groups as shown in
Figure 2 and Table. The 2-year incidences of composite of death, MI or stroke also did
not differ among SES, EES and CABG groups. However, the incidence of ischemia-
driven TVR was lower in the CABG than in the EES or SES groups. Between the EES
and SES groups, the incidences of MACCE and any individual end points were not
different over 2 years.
Conclusion: Stenting with the second-generation EES showed a similar efficacy for
the treatment of ULMCA stenosis, as compared with stenting with the first-eneration
SES or CABG, with regard to the incidence of MACCE over 2 years. Although there
was a tendency of higher repeat revascularization rate after EES than CABG, the two
stent types of EES or SES had comparable long-term safety and efficacy.
Drug Eluting Balloon Releasing Paclitaxel for Treatment of Coronary
Restenosis in Bare Metal- and Drug Eluting Stents: Twelve-Month Follow-Up
Results from the European PEPPER FIM Trial
Chritstoph Hehrlein, Ulrich Dietz, Jacek Kubica, Erik Jorgensen, Ellen Hoffmann,
Christoph Naber, Maciej Lesiak, Henrik Schneider, Marcus Wiemer, Gert Richardt
Background: In-stent restenosis continues to be a therapeutic challenge. The present
study aimed to evaluate safety and efficacy of a drug eluting balloon (DEB) releasing
paclitaxel from a butyryl-tri-hexyl citrate (BTHC) excipient in patients with a single
in-stent restenotic lesion (ISR) in coronary arteries.
Methods: Between August 2009 and April 2010, 81 patients were pre-dilated with an
uncoated balloon and treated with the Pantera Lux Paclitaxel Releasing Balloon at 9
European sites. Dual antiplatelet therapy (DAPT) was recommended for 3 months.
Clinical follow up was performed at 1, 6 and 12 months, and angiographic follow up
at 6 months. The primary endpoint was in-stent late lumen loss at 6 months. A
secondary endpoint was major adverse cardiac event (MACE, a composite of cardiac
death, non-fatal MI, clinically driven target lesion revascularization (TLR) and
clinically driven target vessel revascularization (TVR)) rate at 1, 6 and 12 months.
Results: The majority of restenotic lesions from bare metal 43 (53%) and drug eluting
stents 38 (47%) were core lab classified to Mehran class I (71.6% focal) followed by
class II (19.8% diffuse intra-stent). Device success rate was
98.6%. At 6 months, in-stent late lumen loss was 0.07 ± 0.31 mm and MACE rate was
7.8% (1 peri-procedural MI, 1 TVR and 4 TLR). The preliminary MACE rate at 12
months was 11.7% and was driven by 3 additional TLR. 
Conclusion: Twelve-month preliminary MACE results confirmed safety and efficacy
in a mixed population of BMS-ISR and DES-ISR patients for a novel drug eluting
balloon releasing paclitaxel from the excipient BTHC.
Early Healing of Coronary Stents. Comparative Optical Coherence
Tomography Study. Comparison of the entothelial progenitor cell capturing
stent (GENOUS) with chromium cobalt BLAZER and SOLARFLEX stents and
drug-eluting NOBORI stent.
Ladislav Groch, Anna Kilianova, Ota Hlinomaz, Michal Rezek, Jan Sitar
Background: Most powerful predictor of stent thrombosis is endothelial coverage.
Optical Coherence Tomography (OCT) is due to resolution 10um excelent tool to
assess stent healing.
Methods: In our prospective, single centre, randomized study we compared early (14
days) healing in 40 patients treated for stable/unstable angina or non-sustained
myocardial infarction by percutaneous coronary intervention with stent implantation.
40 patient/44stents were randomized into four groups: 10 patients treated by entothelial
progenitor cell capturing stent (GENOUS chromium cobalt stent), 10 pts by Blazer
stent (chromium cobalt stent), 10 pts by SolarFlex (chromium cobalt stent) and 10pts
by NOBORI stent (biolimus eluting coronary stainless steel stent). The standard
technique of stent implantation – baloon/artery ratio 1:1 and 16 bars implantation
pressure – was used. 14 days after successful stent implantation OCT evaluation was
performed. Stent coverage was divided into 3 categories: malapposed, apposed-
uncovered and covered class. The primary endpoint was the percentage of healing
struts, the secondary endpoints were the absolute thickness of neointima and the
percentage of malapposed struts.Total 4413 struts of stents were manually analyzed.
Results: Results are shown in Table No 1, 2 3 and graph No 1.
The most rapid and the most massive healing was observed in GENOUS stents. Also
the absolut thickness of neointima was the highest in GENOUS stent.
Conclusion: The entothelial progenitor cell capturing GENOUS stent provides the
more rapid healing compared with chromium cobalt stents and drug-eluting stent.The
early healing is the powerfull predictor of subacute and late stent thrombosis. Thus, the
high percentage of covered strus probably enable to minimalize the lenght of dual
antiplatelet therapy, especially in patients with encreased bleeding risk. If our results
can be transfered into clinical praxis must be proven in further studies.
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TA-AVI Using An Investigational Self—Expandable Bioprosthesis: 30 Day
Outcomes
Joerg Kempfert, Markus Schönburg, Helge Möllmann, Ardwan Rastan, David
Holzhey, Hendrik Treede, Stephan Baldus, Matthias Thielmann, Daniel Wendt,
Holger Schröfel, Martin Heimeshoff, Friedrich Mohr, Thomas Walther
Background: Transapical aortic valve implantation (TA-AVI) is a standard approach
for high-risk elderly patients using the balloon expandable Edwards SAPIEN™. As
an alternative we are evaluating the Symetis ACURATE TA™, a new self-expanding
transapical bioprosthesis, in a pilot study.
Methods: This novel device, composed of a porcine biologic valve attached to a self-
expandable nitinol stent, is unsheathed proximally towards the apex and is designed for
anatomical orientation of the commissures and subcoronary implantation using a
simple intuitive two-step deployment. The device accommodates native annular sizes
of 21mm to 27mm. An Ethics Committee approved the study and all patients provided
informed consent.
Results: Fifty (50) patients have been treated. Mean patient age is 83.7 ± 4.3 years,
76% are female and all presented with NYHA Class III/IV with a mean logistic
EuroSCORE of 19.6 ± 6.6% and STS Score of 8.4 ± 8.1%. Forty-seven (47) implants
were delivered successfully in the intra-annular and subcoronary position for a
procedural success rate of 94%. There were 2 conversions to conventional surgery and
1 valve-in-valve implantation. All implants were performed off-pump. To date, at 30
days post-implant, ECHO control reveals 1 patient with paravalvular leak of +2 and the
remainder with ≤ +1 and no incidence of relevant (≥ 1+) central leak. The mean aortic
gradient is 12.5 ± 5.0 mmHg with a mean EOA of 1.3 ± 0.4 cm2. Two patients expired
by 30 days (4% mortality rate): 1 from a nonvalve- related cause (respiratory
complication) and 1 following annular dissection and subsequent conversion to surgery.
There was 1 reported stroke and 7 new pacemaker implants by 30 days.
Conclusion: This preliminary 30 day data indicates good function and outcomes after
TA-AVI using the device in high- risk patients with aortic stenosis. Complete primary
endpoint (30 day) results from the completed study will be presented for the first time
at TCT 2011.
1 Year Outcomes of Trans-catheter Aortic Valve Implantation in the UK:
Comparison of Valve Type and Access Route
Daniel Blackman, Philip MacCarthy
Background: Registry data and recent randomized controlled trials have established
the safety and efficacy of TAVI in certain patients. An effective multidisciplinary “Heart
Team” selects patients who may benefit and tailors therapy accordingly. However, little
is yet known about differences in outcomes after this selection process – according to
valve type and access route. The UK TAVI Registry captures all procedures performed
in the UK and tracks mortality in 100% of patients, making it one of the most
comprehensive TAVI registry datasets available. We present the UK survival of patients
undergoing TAVI at 1 year according to the valve type and the access route.
Methods: 1620 consecutive patients undergoing TAVI from 1st Jan 2007-31st Dec
2010 were analysed. Procedures were performed in 32 centres (experience range n=1-
178). A comprehensive dataset was input via local databases to a central database
(UK-CCAD). Mortality tracking was performed via the NHS Central Register.
Results: Patients formed 4 groups: Trans-femoral (TF) Sapien n=389 (Edwards
Lifesciences, Irvine, US); TF CoreValve n=706 (Medtronic Inc, US); Trans-apical (TA)
Sapien n=410; and Subclavian (SC) CoreValve n=92. Patient characteristics are shown in
Table 1. Outcomes according to group are shown in Table 2. Statistical comparison is
made between the Sapien TF and CoreValve TF groups and the Sapien TA and CoreValve
SC groups because of their broad clinical similarity. Kaplan-Meier curves are shown
comparing Sapien TF vs CoreValve TF (Figure 1) and comparing access route (Figure 2).
Conclusion: These outcomes compare favourably with published series. No difference
is observed between Sapien TF and CoreValve TF at 1yr. Patient risk profile is higher
with Sapien TA/CoreValve SC and mortality is higher in these groups. 30 day mortality
is higher in the Sapien TA group than the CoreValve SC group but there is no difference
at 1 year. The reason for this observation is not clear and requires further study. The
incidence of AR>2+ and need for permanent pacing is greater with CoreValve.
Correlation between Platelet Reactivity and Type of Post-discharge Bleeding
Events in PCI-treated Patients: Results of the ACCEL-BLEED study
Young-Hoon Jeong, Tae Jung Kwon, Udaya S. Tantry, Yongwhi Park, Seok-Jae
Hwang, Kevin P. Bliden, Choong Hwan Kwak, Jin-Yong Hwang, Paul A. Gurbel
Background: The relation of platelet reactivity (PR) to bleeding events in PCI-treated
patients is unclear. Because bleeding events immediately after PCI are influenced by
multiple therapies and risk factors, we evaluated whether PR correlates with post-
discharge bleeding complications.
Methods: PCI-treated patients (n=252) without in-hospital complication were
prospectively enrolled. Platelet measures were assessed in-hospital and at 30-day
follow-up by light transmittance aggregometry (LTA) and VASP-P assay. The primary
end point was the correlation of PR and 30-day incidence of bleeding events assessed
by TIMI bleeding score or detailed BleedScore™.
Results: No patients suffered from TIMI major or minor bleeding. A total of 93 patients
experienced BleedScore™ bleeding events (29.8%), of which 21.9% were superficial,
and 7.9% were internal. Baseline demographics did not significantly differ across the
bleeding type. There were no differences in in-hospital PR depending on the bleeding
type. Compared to other patients, those with an episode of internal bleeding had
significantly lower values of 30-day PR (VASP index, 54.8±17.3% vs. 45.2±18.7%,
p=0.021; 20µM ADP-PR, 50.0±18.9% vs. 37.5±22.8%, p=0.006. By ROC curve
analysis, the optimal cutoffs for predicting internal bleeding were 20µM ADP-PR at 30-
day ≤46% (AUC 0.663, 95% CI 0.525 to 0.802, p=0.016) and VASP index at 30-day
≤45% (AUC 0.640, 95% CI 0.506 to 0.774, p=0.043). In multivariate analysis, 20µM
ADP-PR at 30-day ≤46% was associated with a 4.5-fold increased risk for internal
bleeding. VASP index at 30-day ≤45% was moderately associated with internal
bleeding (OR 2.8, 95% CI 1.0 to 8.0, p=0.051).
Conclusion: Among patients undergoing PCI, ADP-induced platelet reactivity at 30-
day is associated with risk for post- discharge internal bleeding. BleedScore™ bleeding
scale can be utilized to assess detailed safety profile in clinical trials using potent
P2Y12 inhibitors.
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